BB-613 Watch Oximeter

K181006 · Bio-Beat Technologies , Ltd. · DQA · Sep 21, 2018 · Cardiovascular

Device Facts

• Record ID: K181006
• Device Name: BB-613 Watch Oximeter
• Applicant: Bio-Beat Technologies , Ltd.
• Product Code: DQA · Cardiovascular
• Decision Date: Sep 21, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.2700
• Device Class: Class 2

Intended Use

The BB-613 Watch Oximeter is a small, wrist-worn device indicated for use in measuring and displaying functional oxygen saturation of arterial hemoglobin (%SpO2) and pulse rate. It is intended for spot-checking of adult patients in hospitals, clinics, long-term care, and home use.

Device Story

Wrist-worn pulse oximeter; uses pulse reflectance technology. Emits red and infrared light via LEDs into wrist skin; reflected light detected by photodiode. Device processes signals to calculate %SpO2 and pulse rate; displays results on integrated LCD. Used by patients or clinicians in hospitals, clinics, long-term care, or home environments for spot-checking. Provides immediate visual feedback on saturation and pulse; includes indicators for weak or absent signals. Benefits include non-invasive, portable monitoring of oxygenation status. Powered by rechargeable battery.

Clinical Evidence

Clinical validation performed on 10 subjects (ages 18-40, 6 male/4 female) with Fitzpatrick skin types I-V. Compared BB-613 measurements against predicate device. Results showed equivalence in SpO2 measurements; no adverse events observed. Pulse rate validated using custom simulator per ISO 80601-2-61. Biocompatibility testing (cytotoxicity, sensitization, irritation) conducted per ISO 10993-5 and 10993-11.

Technological Characteristics

Wrist-worn device; pulse reflectance sensing using 4 LEDs (650nm Red, 880nm IR) and photodiode. Materials: Polycarbonate, silicone, carbon black, stainless steel. Powered by rechargeable battery. Connectivity: Standalone. Software-controlled. Tested per ANSI/AAMI/IEC 60601-1 (electrical safety), IEC 60601-1-2 (EMC), and IEC 60601-1-11 (home use).

Indications for Use

Indicated for spot-checking functional oxygen saturation of arterial hemoglobin (%SpO2) and pulse rate in adult patients in hospitals, clinics, long-term care, and home settings.

Regulatory Classification

Identification

An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.

Predicate Devices

• Oxitone 1000 (K163382)

Reference Devices

• SPO's PulseOX 7500 (K040178)
• Masimo's Rainbow SET Radical 7R (K100428)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Bio-Beat Technologies Ltd. % Yarmela Pavlovic Partner Hogan Lovells US LLP 3 Embarcadero Center Suite 1500 San Francisco, California 94111

Re: K181006

Trade/Device Name: BB-613 Watch Oximeter Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: DQA Dated: August 30, 2018 Received: August 30, 2018

Dear Yarmela Pavlovic:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You mav, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be avare that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Todd D. Courtney -S

for Tina Kiang, Ph.D. Acting Director Division of Anesthesiology. General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

510(k) Number (if known)

### K181006

Device Name

#### BB-613 Watch Oximeter

Indications for Use (Describe)

The BB-613 Watch Oximeter is a small, wrist-worn device indicated for use in measuring and displaying functional oxygen saturation of arterial hemoglobin (%SpO-) and pulse rate. It is intended for spot-checking of adult patients in hospitals, clinics, long-term care, and home use.

Type of Use (Select one or both, as applicable)

区 Prescription Use (Part 21 CFR 801 Subpart D)

_ Over-The-Counter Use (21 CFR 801 Subpart C)

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# K181006

#### 510(k) SUMMARY

# Bio-Beat Technologies Ltd.'s BB-613 Watch Oximeter

## Submitter

Bio-Beat Technologies Ltd. 26 Magshimim Street Petach Tikva lsrael 44425

Phone: [phone] Facsimile: [phone]

Contact Person: Johanan May

Date Prepared: September 18, 2018

# Name of Device: BB-613 Watch Oximeter

Common or Usual Name: Oximeter

Classification Name: 21 C.F.R. 870.2700 Oximeter

Regulatory Class: Class II

Product Code: DQA

### Predicate Devices

K163382 Oxitone Medical's Oxitone 1000

#### Reference Devices

K040178 SPO's PulseOX 7500 K100428 Masimo's Rainbow SET Radical 7R

### Device Description

The BB-613 device is a wrist-worn device consisting of a light source (LEDs) and sensor array on the backside of the device, with a user interface on the front side of the device. The LEDs transmit light into the subject's skin at their wrist, and part of this light is reflected from the tissue and detected by a photo-diode. The integrated display is used to display the blood saturation and pulse rate results. It also displays symbols that show if there was no signal or a weak signal. The device is powered by a rechargeable battery.

## Intended Use / Indications for Use

{4}------------------------------------------------

The BB-613 Watch Oximeter is a small, wrist-worn device indicated for use in measuring and displaying functional oxygen saturation of arterial hemoglobin (%SpO2) and pulse rate. It is intended for spot-checking of adult patients in hospitals, clinics, long-term care, and home use.

# Comparison of Technological Characteristics and Indications

BB-613 is substantially equivalent to other legally marketed oximeters. Specifically, the BB-613 is substantially equivalent to primary predicate Oxitone Medical's Oxitone 1000 (K163382) and the reference predicates, SPO's PulseOX 7500 (K040178) and Masimo's Radical 7 (K100428). All devices are indicated for measuring and displaying functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate, although the PulseOX 7500 can also store this information. All devices are used in hospitals, clinics, long-term care, and home use, although PulseOX 7500 can also be used in sleep study environments. All devices are indicated for spot-checking of adults except for Radical 7 which is indicated for continuous noninvasive monitoring. The BB-613 has identical indications to the Oxitone 1000 except that it does not have a limitation on compatible wrist size as this limitation is not applicable to the BB-613.

Both the BB-613 and the predicates measure SpO2 by monitoring relative changes to signal intensity of light that has passed through the patient's skin. The devices are similar in regards to the wavelengths of the emitted light and the use of reflected light measurement to assess SpQ2. The devices differ with respect to the specific anatomic structures off of which the light is reflecting. The company has performed clinical validation to show equivalent device performance in regards to SpO2 measurements, and the pulse rate algorithm has been validated per ISO 80601-2-61:2011.

All of the devices are wrist worn and raise similar concerns of biocompatibility of permanent contact device with intact skin. All devices are supplied and used non-sterile. All devices use software to control the device and analyze and display the results. The software has been documented and validated per FDA guidance. All devices contain electronics that present electrical hazard and EMC risks. These risks have been mitigated via IEC 60601 testing. In sum, although there are minor differences in technological characteristics, these differences do not raise different questions and the provided testing establishes equivalent performance as compared to the predicates.

| Item | Subject Device BB-613 | Primary Predicate Oxitone 1000 (K163382) | Reference Device PulseOX 7500 (K040178) | Reference Device Masimo Radical 7 (K100428) |
|------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------|
| Device | BB-613 | Oxitone 1000 | PulseOX 7500 Wrist Device | Rainbow SET Radical 7R |
| Principle of Operation | Pulse reflectance technology, Four LED (red + IR) and photo diode absorbs reflected light | Pulse reflectance technology<br>One LED (red + IR) | Pulse reflectance technology,<br>One LED (red + IR) and photo diode absorbs reflected light | Absorption of red and infrared light |
| Measurement site | Wrist | Wrist | Finger | Finger |

{5}------------------------------------------------

| ltem | Subject Device BB-<br>613 | Primary Predicate<br>Oxitone 1000<br>(K163382) | Reference Device<br>PulseOX 7500<br>(K040178) | Reference Device<br>Masimo Radical 7<br>(K100428) |
|-------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Measurement<br>type | Spot | Spot | Spot | Continuous |
| Emitted light<br>peak<br>wavelength | 880nm (IR), 650nm<br>(Red) | 940nm (IR), 640nm<br>(Red) | 880nm (IR), 650nm<br>(Red) | Not specified |
| Measurement<br>Range SpO2 | 70% to 100% | Not specified | 40% to 99% | 60% to 100% |
| Arms, SpO2 | ±3% | Not specified | ±2% | No motion (adults,<br>pediatrics, infants)<br>60% to 80%: ±3%<br>70% to 100%: ±2% |
| Measurement<br>Range, HR | 40 to 240 bpm | Not specified | 40 to 250 bpm | 25 to 240 bpm |
| Arms, HR | ±3% | Not specified | ±3% | No motion<br>±3 bpm |
| Contact<br>material | Polycarbonate,<br>photodiode window,<br>silicone | Polycarbonate, ABS | Silicone, photodiode<br>window | Not specified |
| Application<br>Method | User wears the<br>device as a watch<br>and powers it on | User wears the<br>device as a watch<br>and powers it on | User wears the device<br>as a watch, places the<br>finger measurement<br>attachment, and powers<br>it on | User wears the device<br>on finger |
| Sterility | Supplied and used<br>non-sterile | Supplied and used<br>non-sterile | Supplied and used non-<br>sterile | Supplied and used<br>non-sterile |
| Data display | LCD on device | LCD on device | LCD on device | LCD on device |
| Data storage | No | No | Yes | Not specified |

# Performance Data

The following tests were performed to demonstrate substantial equivalence:

- . Clinical validation of the oximeter per FDA pulse oximeter guidance on 10 patients with varying Fitzpatrick skin types (I – V). Patient's age ranged from 18 – 40 and 6 were male and 4 were female. Testing showed equivalence to simultaneous measurements from the predicate oximeter. No adverse events were observed.
- Pulse rate validation per ISO 80601-2-61 using a custom built simulator for . reflectance oximetery.
- Software validation per FDA guidance including cybersecurity .
- Electrical safety and EMC testing per ANSI/AAMI/IEC 60601-1 and IEC 60601-1-2 ●
- . Home use validation per IEC 60601-1-11

{6}------------------------------------------------

- Cytotoxicity, sensitization and irritation per ISO 10993-5, and 10993-11 to evaluate . permanent contact of silicone, polycarbonate, carbon black, and stainless steel with intact skin.
# Conclusions

The BB-613 Watch Oximeter is as safe and as effective as the Oxitone 1000. The BB-613 Watch Oximeter has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate device. The minor differences in indications do not alter the intended diagnostic use of the device when used as labeled. In addition, the minor technological differences between the BB-613 Watch Oximeter and its predicate devices do not raise different questions of safety or effectiveness. Performance data demonstrate that the BB-613 Watch Oximeter is as safe and as effective as the predicates. Thus, the BB-613 Watch Oximeter is substantially equivalent.